Overactive Bladder - Results from #2000

Repeat intradetrusor injections of onabotulinum toxin a for refractory idiopathic overactive bladder patients: A single-center experience - Abstract May 8, 2012

The effect of elective sham dose escalation on the placebo response during an antimuscarinic trial for overactive bladder symptoms - Abstract May 7, 2012

The role of serum C-reactive protein in women with lower urinary tract symptoms - Abstract May 4, 2012

Overactive bladder symptoms and voiding dysfunction in neurologically normal women - Abstract May 3, 2012

Environmental cues to urgency and leakage episodes in patients with overactive bladder syndrome: A pilot study - Abstract May 1, 2012

Use of mirabegron in treating overactive bladder - Abstract April 30, 2012

The efficacy of posterior tibial nerve stimulation for the treatment of overactive bladder in women: A systematic review - Abstract April 27, 2012

Overactive bladder? What you should know if you've always ‘gotta go’ April 26, 2012

Fesoterodine in randomised clinical trials: An updated systematic clinical review of efficacy and safety - Abstract April 26, 2012

Persistence with prescribed antimuscarinic therapy for overactive bladder: A UK experience - Abstract April 25, 2012

Overactive Bladder (OAB) Etiology & Clinical Assessment April 25, 2012

Anticholinergic drugs for adult neurogenic detrusor overactivity: A systematic review and meta-analysis - Abstract April 24, 2012

Blood-brain barrier permeation and efflux exclusion of anticholinergics used in the treatment of overactive bladder - Abstract April 11, 2012

Which clinical risk factors determine a pathological urodynamic evaluation in patients with multiple sclerosis? an analysis of 100 prospective cases - Abstract April 9, 2012

Reproducibility of electrical sensory testing in lower urinary tract at weekly intervals in healthy volunteers and women with non-neurogenic detrusor overactivity - Abstract April 2, 2012

EAU 2012 - Comparison of two different Botulinumtoxin A products (Xeomin, Botox) used for detrusor injection in patients with bladder overactivity (BO) – a prospective randomized double-blind study - Session Highlights March 30, 2012

EAU 2012 - The β3-adrenoceptor agonist Solabegron is safe and effective for improving symptoms of overactive bladder - Session Highlights March 30, 2012

EAU 2012 - Health-related quality of life in patients with overactive bladder - Session Highlights March 30, 2012

EAU 2012 - Effect of treatment response on the decision to escalate antimuscarinic dose in elderly subjects with overactive bladder - Session Highlights March 30, 2012

EAU 2012 - Prevalence and clinical features of detrusor underactivity among the community-dwelling elderly with lower urinary tract symptoms: A comparison between men and women - Session Highlights March 30, 2012

Page 101 of 111

SUFU MyBladder app